SCHEMBL4476172

SCHEMBL4476172

C[Si](C)(C)C#Cc1ncc(-c2ccc(Cl)cc2)cc1Br

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
KMT2A Q03164 3/20 0.40
MAPT P10636 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAP4K4 O95819 7/20 0.37
CA12 O43570 1/20 0.37
CA9 Q16790 1/20 0.37
CYP1A2 P05177 4/20 0.35
CYP2C19 P33261 3/20 0.35
CYP3A4 P08684 2/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP2C9 P11712 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
KCNH2 Q12809 1/20 0.34
MINK1 Q8N4C8 1/20 0.34
TNIK Q9UKE5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4478583 0.86 AHR (0.39) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL4480451 0.84 PIK3CD (0.43) NPC1RAB9ASMN1; SMN2KMT2AMAP4K4
SCHEMBL2321892 0.84 CHRM1 (0.47) NPC1RAB9ASMN1; SMN2KMT2AMAP4K4
SCHEMBL4477379 0.81 ALDH1A1 (0.37) NPC1RAB9ASMN1; SMN2KMT2AMAP4K4
SCHEMBL4493198 0.80 MAP4K4 (0.37) NPC1RAB9ASMN1; SMN2MAP4K4CA12
SCHEMBL4482838 0.80 MAP4K4 (0.40) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL10017416 0.75 MAP4K4 (0.49) MAP4K4CYP1A2KCNH2MINK1TNIK
SCHEMBL2322584 0.74 MCHR1 (0.45) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL4477476 0.73 MAP4K4 (0.45) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL4478608 0.72 MCHR1 (0.50) MAP4K4CHRM1HTR2AMCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592358-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-22 US disclosed
EP-1737823-A2 NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS Boehringer Ingelheim International GmbH (DE) 2007-01-03 EP disclosed
WO-2005103002-A2 NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 WO disclosed
US-20050234101-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234101-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, GPR119, MCHR2 NPC1 509/4885RAB9A 3916/4885SMN1; SMN2 2309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.